Blocking fat absorption with orlistat in 5 healthy people did not increase GLP-1, PYY, or satiety, suggesting that post-gastric-bypass hormone changes are not driven by fat malabsorption alone.
No GLP-1 or PYY increaseOrlistat-induced fat malabsorption had no effect on satiety hormones or appetite in 5 healthy participants
What the researchers found
Short-term orlistat-induced fat malabsorption did not increase postprandial GLP-1 or PYY3-36 levels or affect hunger/satiety in normal-weight individuals.
Why it matters
Understanding which mechanisms drive beneficial hormone changes after bariatric surgery could help develop non-surgical treatments for obesity using similar pathways.
The numbers in context
5 participants; orlistat 120 mg x 3 days; no change in GLP-1, PYY3-36, hunger, satiety; increased peak glucose and insulin
How the study worked
Randomized, double-blinded, crossover trial with 5 healthy participants receiving orlistat 120mg or placebo for 3 days, with 14-hour meal test measuring hormones and appetite.
Who was studied
5 healthy normal-weight participants in randomized double-blind crossover
What this study cannot tell us
Very small sample (n=5); short-term (3 days); normal-weight participants — obese individuals may respond differently; orlistat does not perfectly replicate bypass-type malabsorption.
How to read the evidence
Well-designed crossover RCT but extremely small sample size (n=5) limits statistical power and generalizability; negative result requires larger confirmation.
When this study was published
Published in 2020; the mechanisms driving post-bariatric metabolic improvements continue to be actively investigated.
The bigger picture
This negative finding helps narrow the search for what drives post-bypass GLP-1 elevation — ruling out fat malabsorption and pointing toward altered gut anatomy and nutrient delivery patterns.
Questions still open
- What specific mechanism of gastric bypass actually drives the GLP-1 and PYY increases?
- Would longer-term fat malabsorption produce different results?
- Do obese individuals show different hormonal responses to orlistat than normal-weight people?
Common questions
Why does gastric bypass help with weight loss?
Can orlistat increase GLP-1 like gastric bypass?
Read the original research
Short-term intestinal lipase inhibition in normal-weight individuals does not affect postprandial peptide YY3-36 and glucagon-like peptide-1 levels, hunger or satiety.
Diabetes, obesity & metabolism, 22(12), 2499-2503
Citation
Nguyen, Nga N; Kolobova, Irina; Wolfe, Bruce M; Purnell, Jonathan Q. (2020). Short-term intestinal lipase inhibition in normal-weight individuals does not affect postprandial peptide YY3-36 and glucagon-like peptide-1 levels, hunger or satiety.. Diabetes, obesity & metabolism, 22(12), 2499-2503. https://doi.org/10.1111/dom.14182